Fenghuang Zhan
Professor
Also affiliated: University of Iowa (2012–2023); University of Maryland, Baltimore (2003); University of Minnesota (2013); Pennsylvania State University (2013); Hackensack University Medical Center (2003); NewYork–Presbyterian Hospital (2009); Central South University (2023); University of Alberta (2004); Inserm (2002–2003); Changsha Medical University (1998–1999); Duke University (2009); University of Basel (2005); Medical College of Wisconsin (2003); Cornell University (2001–2009); University of Utah (2008–2013); University of Arkansas Medical Center (2020–2023); Huntsman Cancer Institute (2009–2011); University of Iowa Hospitals and Clinics (2015–2017); Aarhus University Hospital (2002); Saint Vincent Health System (2003); Yale University (2009); Centre Hospitalier Universitaire de Montpellier (2002); Cancer Research And Biostatistics (2003–2006); Carver Bible College (2015); Hunan Cancer Hospital (1998–1999); Myeloma UK (2007–2009); Mayo Clinic in Arizona (2009); University of Applied Management Studies (2024); Duke Medical Center (2009); Cancer Research Center (2025); Winthrop Rockefeller Foundation (2020–2025); Hôpital Lapeyronie (2002); Shanghai Tenth People's Hospital (2014); Comprehensive Blood & Cancer Center (2020); Cells Therapy (Poland) (2013); National Cancer Institute (2001–2005); Hôpital Saint Eloi (2003); Institute of Hematology & Blood Diseases Hospital (2016–2019); The US Oncology Network (2009); International Myeloma Foundation (2004); Hainan Provincial Hospital of Traditional Chinese Medicine (2024); European Society for Blood and Marrow Transplantation (2013); Best Biotech (2009); University of Iowa Holden Comprehensive Cancer Center (2015); Zhejiang University (2025); Penn State Milton S. Hershey Medical Center (2013); China Medical University (1996–2015)
Faculty Researcher
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Fenghuang Zhan's research focuses on understanding the molecular mechanisms underlying multiple myeloma, a hematologic malignancy. A significant portion of this work investigates the role of specific genes and regulatory pathways in disease progression and drug resistance. For instance, Zhan has studied how HNRNPA2B1 promotes multiple myeloma by affecting AKT3 expression through the stabilization of ILF3 mRNA, and how FOXM1 regulates glycolysis and energy production in myeloma cells. Other research includes the exploration of chromosomal instability induced by CHEK1 and circCHEK1_246aa, and the modulation of protein deubiquitination by TRIP13 in B cell malignancies.
This research is supported by federal funding, including a $507,317 grant from the NIH/National Cancer Institute for a project aimed at understanding the role and therapeutic potential of drug-resistant genes in multiple myeloma. Zhan's work also addresses disparities in cancer care, with publications examining geographic and racial disparities in access to advanced therapies like CAR-T cells and bispecific antibodies for multiple myeloma, and contributing to consensus recommendations on defining high-risk multiple myeloma. With a substantial publication record (429 publications, h-index of 67, over 19,000 citations), Zhan is recognized as a highly cited researcher.
Metrics
- h-index: 67
- Publications: 434
- Citations: 19,350
Selected Publications
-
Abstract LB220: Can dietary calcium prevent myeloma onset (2026)
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis (2025)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma (2025)
-
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)
-
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)
-
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025)
-
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma (2025)
-
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
-
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)
-
Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma (2024)
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
Federal Grants 2 $507,317 total
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- NEK2 Over-expression Causes Drug Resistance in Myeloma NIH Principal Investigator
- Biological Validation of Candidate Myeloma Driver Genes NIH/Nat. Cancer Institute via Medical College of Wisconsin Principal Investigator
- Novel NEK2 signaling pathways in myeloma progression NIH Principal Investigator
- Gene expression profiling vs MRD assessment in Myeloma NIH Co-Investigator
- U54 - Administrative Core NIH/Nat. Cancer Institute via Baylor College of Medicine Principal Investigator
- Center for Molecular Interactions in Cancer (CMIC) NIH Co-Investigator
- U54 - Bioinformatics Core NIH/Nat. Cancer Institute via Baylor College of Medicine Principal Investigator
- Targeting NEK2 Enables Immune Checkpoint Blockade in High-Risk/Relapsed Myeloma The Paula and Rodger Riney Foundation Principal Investigator
- Toward improvement of BCMA/CST6-CAR-T therapy to target both myeloma cells and bone resorption Leukemia & Lymphoma Society Principal Investigator
- CD24 Tumor-Initiating Cell as a Novel Therapeutic Target in Myeloma US Department of Defense Principal Investigator
- Project 1 – Prevention of MGUS progression to MM by modulating the bone marrow microenvironment NIH/Nat. Cancer Institute via Baylor College of Medicine Principal Investigator
- Retinoid Based Treatment Approaches to Target the Myeloma Stem Cell NIH Principal Investigator
Collaboration Network
Top Collaborators
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Showing 5 of 47 shared publications
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 44 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Showing 5 of 43 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Showing 5 of 42 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Showing 5 of 42 shared publications
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 35 shared publications
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 24 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity
Showing 5 of 21 shared publications
- FOXM1 regulates glycolysis and energy production in multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 21 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
Showing 5 of 21 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 17 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 17 shared publications
- FOXM1 regulates glycolysis and energy production in multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 16 shared publications
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 15 shared publications
- GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Decreased bone resorption in Ezh2 myeloid cell conditional knockout mouse model
Showing 5 of 12 shared publications
Similar Researchers
Based on overlapping research topics